Antisense modulation of BCL2-associated X protein expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsHong Zhang, Andrew T. Watt
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of BCL2-associated X protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BCL2-associated X protein. Methods of using these compounds for modulation of BCL2-associated X protein expression and for treatment of diseases associated with expression of BCL2-associated X protein are provided.
Claims20
A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding BCL2-associated X protein, wherein said compound specifically hybridizes with said nucleic acid molecule encoding BCL2-associated X protein and inhibits the expression of BCL2-associated X protein.
A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding BCL2-associated X protein.
Dependencies are inferred from the claim text.